CA 19-9: handle with care
Open accessThe DOI matches its Crossref record.
Abstract
Since its inception in the mid-1980s of the 20th century testing for carbohydrate antigen 19-9 (CA 19-9) has raised expectation for an earlier diagnosis and accurate monitoring of several malignant diseases. After almost 30 years, the available evidences have confirmed the appropriateness and usefulness of determining CA 19-9 levels as a prognostic indicator and as a reliable tool for monitoring pancreatic and gastrointestinal cancer, but concerns have been raised about its applications in screening, which is actually not recommended, and in the diagnosis of malignancies, due to several interferences that limit the specificity and to the insufficient sensitivity of this marker. In this paper we aimed to review the basic concepts of CA 19-9 testing and its current applications, with a major focus on the most recent evidences dealing with assay interference, methods comparison and monitoring of malignant diseases. The prognostic value and monitoring recommendations for pancreatic, gastric and colorectal cancers are described in depth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Direct detection of early-stage cancers using circulating tumor DNA
Phallen, J., Sausen, M., Adleff, V., Leal, A., Hruban, C., White, J., Anagnostou, V., Fiksel, J., Cristiano, S., Papp, E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan2415 · Cited by 1,119
CA 19-9: Biochemical and Clinical Aspects
Scarà, S., Bottoni, P., & Scatena, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_15 · Cited by 351
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
Zhang, Y., Yao, Y., Xu, Y., Li, L., Gong, Y., Zhang, K., Zhang, M., Guan, Y., Chang, L., Xia, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20162-8 · Cited by 300
Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer
Mellby, L. D., Nyberg, A. P., Johansen, J. S., Wingren, C., Nordestgaard, B. G., Bojesen, S. E., Mitchell, B. L., Sheppard, B. C., Sears, R. C., & Borrebaeck, C. A. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6658 · Cited by 159
Introduction to glycopathology: The concept, the tools and the perspectives
Gabius, H.-J., & Kayser, K. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-4 · Cited by 31
“Their availability opens the door to comparative studies of glycan sequences in clinical specimens in the quest to define glycobiomarkers for diseases such as cancer, CA19-9 being an example [13-15].”
Background
Metadata
- Authors
- Galli, C., Basso, D., & Plebani, M.
- Venue
- Clinical Chemistry and Laboratory Medicine
- Publisher
- Walter de Gruyter GmbH
- Published
- 2013-01-01
- Volume
- 51
- Issue
- 7
- Pages
- 1369-83
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W1995740214
- Cited by
- 104
- References
- 0
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CA 19-9: handle with care. https://app.cochat.ai/papers/10.1515/cclm-2012-0744
- The paper
- Galli, C., Basso, D., & Plebani, M. (2013). CA 19-9: handle with care. Clinical Chemistry and Laboratory Medicine. https://doi.org/10.1515/cclm-2012-0744
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.